Mild Hypertension Clinical Trial
Official title:
Protocol H8D-MC-EMBH PPAR Alpha (LY518674): a Phase 2 Dose-Response Study to Evaluate the Blood Pressure-Lowering Effect in Essential Hypertension
The primary objective of this study is to test the hypothesis that LY518674, administered for 6 weeks to patients with mild hypertension, reduces Systolic Blood Pressure, compared with placebo.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01331486 -
Nitric Oxide Mediated Vasodilatory Response to Hawthorn Standardized Extract
|
Phase 1 | |
Not yet recruiting |
NCT04908917 -
Reducing Air Pollution to Lower Blood Pressure
|
N/A | |
Completed |
NCT03714776 -
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure
|
Phase 2 |